Tag: HYBRIGENICS
Hybrigenics: the Ansel family enters the capital
(CercleFinance.com) – Hybrigenics announced yesterday evening that it had validated during its board of directors the agreement concluded between DMS Group and the Ansel family relating to the sale by…
Hybrigenics: 60 million euros in turnover targeted by 2025 – 05/12/2022 at 12:20
(CercleFinance.com) – Hybrigenics unveiled on Monday the objectives of its latest strategic plan, which notably show a forecast of turnover of 60 million euros by 2025. In a press release,…
HYBRIGENICS: Hybrigenics unveils the objectives of its strategic plan: EUR 60 million in sales targeted by 2025 – 05/12/2022 at 08:00
Ambition: accelerate synergies between subsidiaries to become a key player in the field of drug development Illkirch, December 5, 2022 – Hybrigenics SA (Euronext Paris – FR0004153930 – ALHYG) presented…
HYBRIGENICS: Videoconference for Hybrigenics shareholders and all individual investors on November 30, 2022 at 6:30 p.m. – Presentation of the strategic plan – 11/16/2022 at 6:00 p.m.
Illkirch, November 16, 2022 – 6 p.m. – On the occasion of the presentation of the new strategic plan which aims to guide the company’s strategy in the value chain…
Hybrigenics’ strategic plan in the value chain of therapeutic treatments – 07/11/2022 at 18:22
(AOF) – Following the approval of the Board of Directors, Léone Atayi, Chief Executive Officer of Hybrigenics SA will present on November 30, 2022 the strategic plan which aims to…
HYBRIGENICS: 2022 half-year results – 2022-11-02 at 6:00 p.m.
At its meeting of October 31, 2022, the Board of Directors of Hybrigenics SA (Euronext Paris – FR0004153930 – ALHYG) approved the parent company financial statements for 1 er half…
Hybrigenics: green light from the FDA for its devices in the USA – 06/27/2022 at 17:56
(CercleFinance.com) – Hybrigenics announces that its subsidiary Stemcis, specialized in the treatment of adipose tissue and stem cells in the context of plastic and reconstructive surgeries, has received the clearance…
Stemcis (Hybrigenics): green light from the FDA to market its medical devices – 06/27/2022 at 18:21
(AOF) – Stemcis, a subsidiary of Hybrigenics SA, specializing in the treatment of adipose tissue, mesenchymal stem cells and their uses in plastic and reconstructive surgery, has announced that it…
Hybrigenics: green light from the FDA for its devices in the USA
(CercleFinance.com) – Hybrigenics announces that its subsidiary Stemcis, specialized in the treatment of adipose tissue and stem cells in the context of plastic and reconstructive surgeries, has received the clearance…
Hybrigenics: distribution agreement in the United States for Stemcis
By Olivier Cheilan Published on 06/07/2022 at 6:06 p.m. Photo credit © Reuters …
Hybrigenics: training partnership around the MYFILL kit
(CercleFinance.com) – Hybrigenics announces that its subsidiary Stemcis, which specializes in the treatment of adipose tissue, mesenchymal stem cells and their uses in plastic surgery, has entered into a strategic…
Hybrigenics: operating loss reduced to -0.1 ME
By Claude Leguilloux Published on 04/29/2022 at 7:12 p.m. Photo credit © Reuters …